Stock Market Reviews

PTGX (Protagonist Therapeutics, Inc.) News

Get the latest news, insights, and market updates on PTGX (Protagonist Therapeutics, Inc.). Explore the news page 2 on MyTopStock.com for investor discussions, analysis, and real-time stock performance coverage.

• Regeneron (REGN) Q3 Earnings and Revenues Surpass Estimates
  Regeneron (REGN) delivered earnings and revenue surprises of +25.32% and +4.38%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
  Oct 28, 2025 - $PTGX
• Protagonist Therapeutics Says Icotrokinra Showed 'Meaningful' Outcomes in Ulcerative Colitis Phase 2 Trial
  Protagonist Therapeutics (PTGX) said Monday that new data from two clinical studies of its investiga
  Oct 27, 2025 - $PTGX
• Protagonist Announces New Icotrokinra Data in Ulcerative Colitis and Plaque Psoriasis Presented at Two Recent Medical Conferences
  Icotrokinra demonstrated clinically meaningful outcomes at Week 28 in the Phase 2b ANTHEM-UC study in ulcerative colitis, with 31.7% of patients achieving clinical remission and 38.1% showing endoscopic improvement versus placebo Updated ANTHEM-UC ...
  Oct 27, 2025 - $PTGX
• High Growth US Tech Stocks To Watch In October 2025
  As of October 2025, the U.S. stock market has been experiencing significant volatility, with major indices like the Nasdaq and S&P 500 rebounding sharply after recent declines due to geopolitical tensions. This dynamic environment underscores the importance of identifying high-growth tech stocks that can capitalize on evolving market conditions, particularly those demonstrating resilience and innovation in response to global economic shifts.
  Oct 14, 2025 - $PTGX
• J&J in talks to acquire Protagonist Therapeutics
  The acquisition would grant J&J access to rusfertide, which has demonstrated promise in late-stage trials for polycythaemia vera.
  Oct 13, 2025 - $PTGX
• Protagonist Therapeutics Stock Gains 30% as J&J Reportedly Eyes Deal
  PTGX shares jump 30% after reports that J&J is in talks to acquire the biotech firm amid ongoing negotiations.
  Oct 13, 2025 - $PTGX
• Sector Update: Health Care Stocks Decline Late Afternoon
  Health care stocks were lower late Friday afternoon, with the NYSE Health Care Index down 1.4% and t
  Oct 10, 2025 - $PTGX
• Trump's China tariff threat sinks stocks, Applied Digital surges
  Yahoo Finance Anchor Josh Lipton reports on three stories Wall Street is watching in the latest Market Minute: US stocks tumble as US-China trade tensions intensify, Protagonist Therapeutic (PTGX) shares surge on WSJ reports of acquisition talks with Johnson & Johnson (JNJ), and Applied Digital (APLD) stock is climbing after posting its fiscal Q1 earnings report. Stay up to date on the latest market action, minute-by-minute, with Yahoo Finance's Market Minute.
  Oct 10, 2025 - $PTGX
• Why Protagonist Therapeutics Stock Skyrocketed by Almost 30% Today
  The company could soon be swallowed by a very large peer -- which also happens to be a business partner.
  Oct 10, 2025 - $PTGX
• Protagonist Stock Surges on Johnson & Johnson Report
  Protagonist Therapeutics shares soared 30% Friday after The Wall Street Journal reported that the biopharma company was in talks with Johnson & Johnson about a possible acquistion. See more of the exclusive ...
  Oct 10, 2025 - $PTGX